In vivo pharmacodynamics (PD) evaluations involve assessing thebiological effects of a drug within a living organism. These evaluations are designed to determine the drug's efficacy, mechanism of action, therapeutic index, and potential side effects. Typically conducted using animal models, in vivo PD evaluations help researchers understand how a drug interacts with physiological systems, its relationship to dosage, and the overall impact on health outcomes. Such studies are essential for drug development, aiding in the transition from preclinical research to clinical trials.
New generation therapies, such as anti-tumor targeted drugs, immunotherapy, and gene therapy, have achieved significant success in the treatment of malignant tumors and have great potential for clinical application. These therapies are the key focus of future anti-tumor research. Suitable animal models can help scientists replicate physiological and pathological conditions similar to human tumor development, enabling more accurate candidate drug screening and efficacy evaluation, providing a competitive edge in the increasingly competitive field of new drug development.
Shanghai Model Organisms has established a comprehensive and professional tumor efficacy evaluation platform with hundreds of tumor efficacy evaluation models. This platform provides clients with preclinical services, including candidate drug screening, pharmacological and efficacy evaluation, pharmacokinetics evaluation, and early toxicology evaluation.
The genetically modified spontaneous tumor models are constructed by altering the genes of mice to develop spontaneous tumors.Typically, this involves gene modifications targeting oncogenes or tumor suppressor genes, where disrupting or regulating their expression can induce tumor formation. GenoBioTX has independently developed a variety of spontaneous tumor mouse models to supportpreclinical drug development.
Many cancer drug targets are found in the immune system or tumor microenvironment rather than on the tumor itself. Wild-type mice lackhumanized targets, making them unsuitable for evaluating these drugs. To address this, GenoBioTX has developed proprietary humanizedmouse models, including immune checkpoint and cytokine/receptor humanized mice, ideal for assessing the efficacy and safety oantibody-based therapies.
The NMG severely immunodeficient mice and their derivatives,independently developed by GenoBioTX, can eficiently engraft HU-HSc andHU-PBMC, enabling the reconstruction of a human immune system in mice. These humanized immune system mouse models bettersimulate human immune characteristics and serve as esential tools for studying human immune function,infectious diseases, diabetes.tumorimmunology,and stem cell biology.
Please fill in the order form and we will contact you within 2 working days.
